VahatiCor Closes Oversubscribed Series B Financing to Accelerate A-FLUX® Development for Coronary Microvascular Dysfunction.
The new capital will advance the SERRA-I early feasibility study, engineering development, and preparation for additional studies on coronary microvascular dysfunction. SANTA CLARA, Calif.–(BUSINESS WIRE)–VahatiCor, a medtech company transforming cardiac care for Coronary Microvascular Dysfunction…